Francesca Barone

@ParadeMagazine recently featured Kyle Donahue’s remarkable story of her five-year journey with #glioblastoma and her experience in our phase 1b clinical trial of linoserpaturev (CAN-3110). parade.com/health/kyle-do… #ClinicalResearch #PatientStory #Immunotherapy $CADL

Stories like this remind us why we do what we do: parade.com/health/kyle-do… The journey of Kyle Donahue, featured in Parade, is both deeply personal and scientifically meaningful. Diagnosed with recurrent glioblastoma and initially given only months to live, she is now a five-year survivor after participating in a clinical trial of linoserpaturev (CAN-3110). Clinical trials are where hope meets science. For a disease where median survival is typically measured in months and long-term survival remains rare, such outcomes are extraordinary, and instructive. What stands out is not only the individual story, but what it represents: The potential of viral immunotherapy to reshape the tumor microenvironment. The importance of activating the immune system in ways that may lead to durable responses. And critically, the indispensable role of patients who choose to participate in clinical trials. In glioblastoma, progress has been frustratingly slow for decades. But we are now seeing signals that suggest we may finally be turning a corner. We should be careful not to overinterpret early data. Yet we should be equally careful not to underestimate what these signals mean for patients and for the field.

The treatment paradigm for newly diagnosed, localized prostate cancer is evolving but important gaps remain. In an insightful discussion, Dr. Neal Shore highlights a key reality: many patients pursuing curative intent are still faced with trade-offs that meaningfully impact quality of life. Despite progress, ~30% of patients still experience treatment failure with current radiation or surgical approaches. At the same time, patients are becoming more vocal about avoiding androgen deprivation therapy (ADT), given its well-known effects on fatigue, cognition, sexual function, and cardiovascular health. This is driving a clear shift, toward: - Precision, image-guided interventions. - Local therapies that enhance efficacy without systemic burden. - New combinations that preserve quality of life. Aglatimagene besadenovec (CAN-2409) aims to do exactly that: improve outcomes while potentially avoiding testosterone suppression. The direction is clear: Patients want treatments that are not only effective but also compatible with long-term health and daily life. That is the bar we should all be aiming for. urotoday.com/video-lectures…

Thrilled to share an important milestone for Candel Therapeutics. Our abstract with new data has been selected for oral plenary presentation in the session “Practice-changing, Paradigm-shifting Clinical Trials in Urology” at the American Urological Association Annual Meeting 2026 in Washington, D.C. (May 15–18, 2026). globenewswire.com/news-release/2…

@oshea9_harry @paulpetertak We observed in other indications such impressive increase in the activation status of immune cells that we estimate the target number for recruitment of the PRTK05 study will be sufficient to show differences, we will report median, mean and FC from baseline and against controls.

@baroneExpMed @paulpetertak I gathered that much The descriptive statistics will tell us what about MOA? Is really just tumor expression and biomarkers to mechanically map MOA? These appear solely in experimental and absent control? Something to that extent. Be as jargon laced as you want

@oshea9_harry @paulpetertak We don’t need to prove our MOA as this has been demonstrated through several experiments in preclinical models and clinical trials in other indications.

@oshea9_harry @paulpetertak We added 15 controls and extend the timeline to accommodate for it. This is an experimental medicine biomarker study and we will use descriptive statistics.

@paulpetertak @paulpetertak Why the recent increase to 45 and extended completion date of august? Is 45 enough? Wouldn’t you need minimum in control and experimental? clinicaltrials.gov/study/NCT07332…

How Candel’s linoserpaturev (CAN-3110) Works to Treat Glioblastoma. #CandelTherapeutics #viral #immunotherapy #linoserpaturev #CAN-3110 #glioblastoma #glioma #braincancer #survival $CADL curetoday.com/view/how-can-3…

I’m proud to share a significant step forward for Candel Therapeutics: Positive Interim Data for CAN-3110 in Recurrent Glioblastoma & New Publication in Science Translational Medicine. Today, we announced positive interim survival results from our phase 1b study of CAN-3110 (linoserpaturev) in recurrent glioblastoma, alongside a landmark publication titled “Serial Multiomics Uncovers Anti-Glioblastoma Responses Not Evident by Routine Clinical Analyses” in Science Translational Medicine. I want to thank our extraordinary team at Candel, our clinical collaborators (especially @EAChiocca and the Break Through Cancer TeamLab partners), and the courageous patients participating in this study. This is another step in our mission to bring meaningful therapies to patients facing the toughest cancers. globenewswire.com/news-release/2…

Impressive to get so many things wrong in one report by Jacob Plieth from @ApexOnco . 1. The name of CAN-2409 is aglatimagene besadenovec, not agla-vec. 2. The data of the phase 2a clinical trial of CAN-240 in NSCLC has never disappointed. They are in fact very encouraging, reason why the presentation by Professor Charu Aggarwal was selected for oral presentation at World Lung 2025 and why Candel recently had a very constructive end of phase 2 meeting with the FDA. This data also resulted in Fast Track Designation from the FDA; the promising overall survival data got even stronger after prolonged follow up: mOS of 24.5 months after CAN-2409 treatment in NSCLC patients with an inadequate response to immune checkpoint inhibitors in the per protocol population, mOS of 21.5 months after CAN-2409 treatment in NSCLC patients with progressive disease despite immune checkpoint inhibitor in the per protocol population, regression of uninjected lesions in ~two-thirds of patients presenting with multiple lesions, a long tail of survival:37% of patients alive > 2 years after CAN-2409 administration in patients with progressive NSCLC at time of enrollment, mOS of 25.4 months after CAN-2409 treatment in non-squamous NSCLC patients (target population) with progressive disease despite ICI in the per protocol population. To the best of our knowledge, we are not aware of more encouraging data in a comparable population with similar unfavorable baseline prognostic factors (see Candel's corporate slide deck). 3. In this open label phase 2 clinical trial in therapy-resistant cancer, we selected a patient population with known unfavorable prognostic factors: most patients had tumors exhibiting undetectable or low PD-L1 expression; 11% of the patients were current smokers, and > 80% had failed to demonstrate response to both platinum-based chemotherapy and ICI therapy. In standard clinical practice, patients in this population typically discontinue ICI therapy upon disease progression and transition to second-line docetaxel chemotherapy, which is consistently associated with a mOS of less than 12 months. In this population of patients with largely metastatic, progressive cancer despite optimal standard of care, there are unfortunately no placebo effects, there is no regression to the mean or impact of expectation bias. It appears unlikely that the striking OS results reported can be explained by a disproportionately favorable prognostic profile in the evaluable population compared to the enrolled population: comparison of the baseline demographics and characteristics suggests that the evaluable population was representative of the overall study population. These results provide the rationale for a randomized phase 3 clinical trial, which we are preparing for. 4. It's clear that Jacob Plieth did not listen to the presentation at World Lung, as he consistently refers to Professor Aggarwal as 'he' rather than 'she'. 5. It is also incorrect that only data on patients have been presented who received the per protocol regimen of 2 administrations of CAN-2409 plus valacyclovir (the second administration is the booster). Although this early-phase trial for internal decision making was not formally designed for an intention-to-treat (ITT) analysis, an exploratory analysis in the non-squamous population (the target population for this program) showed a mOS of 16.9 months in the ITT — markedly longer than the 12.3-month benchmark reported with docetaxel in this setting. This is all in the corporate slide deck and therefore already in the public domain. 6. ORR data has been presented before. Given the observed pseudo-progression in our trial due to immune cell infiltration (a positive effect!), shown in serial biopsy samples (the gold standard), OS remains the most reliable clinical endpoint, as surrogate markers like ORR may be confounded. This is consistent with the recommendations by SITC and the 'new FDA'. 7. It's not a 'puzzling fact' that Candel doesn't expect to file in the US until Q4 2026, as we have been absolutely clear that we will use this time to scale up commercial manufacturing and put the product on stability, while getting ready for launch excellence. We are on track. See recent Fireside Chats where this is discussed in more detail. 8. The comments about the SPA are also completely wrong and misleading, as Candel has strictly adhered to the agreement with the FDA and the SPA is intact. Being a journalist comes with a responsibility. Happy to discuss and debate data any time in the context of seeking the truth - nothing about that is personal. World Lung 2025 – Candel looks to a new agla-vec use oncologypipeline.com/apexonco/world…

Dr. Charu Aggarwal from @PennMedicine is presenting CAN-2409 NSCLC data at @IASLC 2025. Candel’s phase 2a trial in ICI-resistant patients showed 21.5 months median OS vs 9.8-11.8 months with standard chemotherapy. wclc.iaslc.org #WCLC25 #LungCancer #ClinicalData

Our CEO @paulpetertak will present at the 44th Annual Canaccord Genuity Growth Conference. Be sure to connect with us if you're attending the conference. ir.candeltx.com/news-releases/… $CADL

I'm delighted to join MIB’s newly formed Scientific Advisory Board alongside a group of outstanding experts! linkedin.com/posts/francesc…

Great day for ⁦@CandelTx⁩ !!!! linkedin.com/posts/francesc…

Join our investor conference call on Tuesday, June 3 at 1:00 PM ET following our #ASCO25 presentation. Our management team & leading prostate cancer specialists will discuss our phase 3 CAN-2409 results. Find more details here: ir.candeltx.com/news-releases/… $CADL #ProstateCancer

Candel Therapeutics is set to host a webcast and conference call on Tuesday, June 3, 2025, at 1:00 PM ET. The event will delve into the promising phase 3 clinical results for CAN-2409 in localized, intermediate-to-high risk prostate cancer. These results showcased a notable 30% decrease in disease recurrence compared to a placebo when used alongside standard-of-care radiation therapy. The discussion stems from Dr. Theodore DeWeese’s presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. Joining the conversation will be esteemed specialists in the field of prostate cancer, including John E. Sylvester, M.D., from Atlantic Urology Clinics in Myrtle Beach, South Carolina, and Ronald F. Tutrone, Jr., M.D., FACS, CPI, National Medical Director of Clinical Research at United Urology Group in Towson, Maryland. Both physicians played pivotal roles as principal investigators during the phase 3 clinical trial. For more details, you can refer to the official announcement here: globenewswire.com/news-release/2…

New in @NeuroOnc! Our phase 1b trial of CAN-2409 + nivolumab in newly diagnosed high-grade glioma shows promising safety & survival data with immune activation supporting CAN-2409's pan-tumor potential. Read more: ir.candeltx.com/news-releases/… $CADL

Combination of surgical upfront immunotherapy with aglatimagene besadenovec (CAN-2409), followed by chemoradiation and then adjuvant nivolumab for newly diagnosed glioblastoma (Wen et al. March 2025, @NeuroOnc). @EAChiocca & @paulpetertak

The collaboration between Candel Therapeutics and IDEA Pharma comes at a critical time as we prepare for our BLA submission for CAN-2409 in prostate cancer. Candel will gain access to a dedicated team of experts with extensive experience in oncology commercialization and go-to-market strategy optimization, while Candel continues to lead the overall commercial strategy. Looking forward to working together with the best of the best on the path to market. globenewswire.com/news-release/2…

Molecular and spatial analysis of tertiary lymphoid structures in Sjogren’s syndrome nature.com/articles/s4146… @NatureComms @baroneExpMed